secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001193125-26-092748
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.
- Split effective 5:00 p.m. ET on March 6; trading on split-adjusted basis begins March 9.
- New CUSIP 79400X602; fractional shares cashed out at closing price on March 6.
- Equiniti Trust Company acting as exchange agent; all options and warrants adjusted proportionally.
- Stockholders approved reverse split range of 1-for-4 to 1-for-15; Board chose 1-for-12 ratio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/0001193125-26-092748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/dcoy-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-092748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer